Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 10/20 | 0.70 |
| ▸ | CTSK | P43235 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 2/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CTSH | P09668 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564477 | 1.00 | CTSC (0.70) | CTSCCTSKCTSSCTSLCYP1A2 | |
| SCHEMBL4425402 | 0.86 | CTSC (0.71) | CTSCCTSKCTSSCTSLCYP1A2 | |
| SCHEMBL5906582 | 0.86 | CTSC (0.71) | CTSCCTSKCTSSCTSLCYP1A2 | |
| SCHEMBL334424 | 0.85 | CTRB1 (0.57) | CTSCCTSKCTSSCTRB1 | |
| SCHEMBL2843211 | 0.85 | CTRB1 (0.57) | CTSCCTSKCTSSCTRB1 | |
| SCHEMBL334301 | 0.85 | CTRB1 (0.57) | CTSCCTSKCTSSCTRB1 | |
| SCHEMBL10403423 | 0.83 | CTRB1 (0.55) | CTSCCTSKCTSSCYP1A2CTRB1 | |
| SCHEMBL8327832 | 0.83 | CTSC (1.00) | CTSCCTSKCTSSCTSLCYP1A2 | |
| SCHEMBL10961618 | 0.82 | CTSL (0.70) | CTSCCTSKCTSSCTSLCYP1A2 | |
| SCHEMBL5186109 | 0.82 | CTSC (0.75) | CTSCCTSKCTSSCTSLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183443-B2 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2007-02-27 | — | — | US | disclosed |
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP ASSETS B.V. (NL) | 2005-09-29 | — | — | US | disclosed |
| EP-1352894-A1 | Process for the preparation of enantiomerically enriched compounds | DSM IP Assets B.V. (NL) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215822-A1 | Process for the preparation of enantiomerically enriched compounds | ADH1C, ADH1A, ADH5 | CTSC 899/4885CTSK 3479/4885CTSS 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.